Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
SCOTTSDALE, Ariz., Jan. 02, 2024 (GLOBE NEWSWIRE) — Journey Medical Corporation (Nasdaq:DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company has entered into a credit facility with an affiliate of SWK Holdings Corporation (“SWK”), a specialized finance company with a focus on the global healthcare sector, providing for borrowings of up to $20 million (“Credit Facility”).
Related news for (FBIO)
- Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
- Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
- Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights
- Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform
- Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT